Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Wednesday

Enliven Therapeutics (NASDAQ:ELVN) is projected to release its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.4479) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Enliven Therapeutics to post ($1.79) EPS for the current fiscal year and ($2.26) EPS for the next fiscal year.

Enliven Therapeutics Trading Up 0.4%

Shares of NASDAQ ELVN opened at $44.83 on Wednesday. The firm has a 50-day simple moving average of $48.07 and a 200-day simple moving average of $42.76. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32.

Analysts Set New Price Targets

ELVN has been the subject of several research reports. Mizuho upped their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 target price on the stock. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. The Goldman Sachs Group upped their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, HC Wainwright increased their price target on Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 19th. Ten analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Insider Activity

In other Enliven Therapeutics news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 31,054 shares of company stock worth $1,493,823. Corporate insiders own 3.00% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.